Abstract:Background: Placenta-derived human mesenchymal stem cells (PL-MSCs) have gained a lot of attention in the field of regenerative medicine due to their availability and bone-forming capacity. However, the osteogenic differentiation capacity of these cells remains inconsistent and could be improved to achieve greater efficiency. Although metformin, a widely used oral hypoglycemic agent, has been shown to increase bone formation in various cell types, its effect on osteogenic differentiation of PL-MSCs has not yet been investigated. Therefore, the objective of this study was to examine the effect of metformin on the osteogenic differentiation capacity of PL-MSCs and the underlying mechanisms. Methods: The PL-MSCs were treated with 0.5 to 640 µM metformin and their osteogenic differentiation capacity was examined by an alkaline phosphatase (ALP) activity assay, Alizarin red S staining and expression levels of osteogenic genes. The role of adenosine 5'-monophosphate-activated protein kinase (AMPK) signaling in mediating the effect of metformin on the osteogenic differentiation capacity of PL-MSCs was also investigated by determining levels of phosphorylated AMPK (pAMPK)/AMPK ratio and by using compound C, an AMPK inhibitor. Results: The results showed that 10-160 µM metformin significantly increased the viability of PL-MSCs in a dose- and time-dependent manner. Furthermore, 80-320 µM metformin also increased ALP activity, matrix mineralization, and expression levels of osteogenic genes, runt-related transcription factor 2 (RUNX2), osterix (OSX), osteocalcin (OCN) and collagen I (COL1), in PL-MSCs. Metformin increases osteogenic differentiation of PL-MSCs, at least in part, through the AMPK signaling pathway, since the administration of compound C inhibited its enhancing effects on ALP activity, matrix mineralization, and osteogenic gene expression of PL-MSCs. Conclusions: This study demonstrated that metformin at concentrations of 80-320 μM significantly enhanced osteogenic differentiation of PL-MSCs in a dose- and time-dependent manner, primarily through activation of the AMPK signaling pathway. This finding suggests that metformin could be used with other conventional drugs to induce bone regeneration in various bone diseases. Additionally, this study provides valuable insights for future osteoporosis treatment by highlighting the potential of modulating the AMPK pathway to improve bone regeneration.

Metformin Regulates Differentiation of Bone Marrow-Derived Endothelial Progenitor Cells Via Multiple Mechanisms.

Metformin Inhibits Endothelial Progenitor Cell Migration by Decreasing Matrix Metalloproteinases, MMP-2 and MMP-9, Via the AMPK/mTOR/autophagy Pathway.

Metformin inhibits angiogenesis in endothelial progenitor cells through inhibiting MMP 2 , MMP 9 and uPA expression via AMPK-mTOR-autophagy pathway

Metformin inhibits angiogenesis of endothelial progenitor cells via miR-221-mediated p27 expression and autophagy.

Metformin induces osteoblastic differentiation of human induced pluripotent stem cell‐derived mesenchymal stem cells

Metformin Enhances the Differentiation of Dental Pulp Cells into Odontoblasts by Activating AMPK Signaling

Metformin enhances osteogenic differentiation of BMSC by modulating macrophage M2 polarization

Metformin Facilitates Osteoblastic Differentiation and M2 Macrophage Polarization by PI3K/AKT/mTOR Pathway in Human Umbilical Cord Mesenchymal Stem Cells

Metformin Promotes Differentiation and Attenuates H2O2-Induced Oxidative Damage of Osteoblasts via the PI3K/AKT/Nrf2/HO-1 Pathway

Improvement of osteogenic differentiation potential of placenta-derived mesenchymal stem cells by metformin via AMPK pathway activation

Metformin Rescues the Impaired Osteogenesis Differentiation Ability of Rat Adipose-Derived Stem Cells in High Glucose by Activating Autophagy

Role of Metformin on Osteoblast Differentiation in Type 2 Diabetes

Metformin promotes cell proliferation and osteogenesis under high glucose condition by regulating the ROS‐AKT‐mTOR axis

Metformin inhibits nerve growth factor-induced sympathetic neuron differentiation through p35/CDK5 inhibition

Metformin Promotes the Proliferation and Differentiation of Murine Preosteoblast by Regulating the Expression of Sirt6 and Oct4

Metformin impacts the differentiation of mouse bone marrow cells into macrophages affecting tumour immunity

Metformin Induces Differentiation in Acute Promyelocytic Leukemia by Activating the MEK/ERK Signaling Pathway.

Metformin-mediated effects on mesenchymal stem cells and mechanisms: proliferation, differentiation and aging

Regulation of myoblast differentiation by metabolic perturbations induced by metformin

Metformin activates AMPK and mTOR to Inhibit RANKL-stimulated osteoclast formation

Antioxidant and Anti-Senescence Effect of Metformin on Mouse Olfactory Ensheathing Cells (mOECs) May Be Associated with Increased Brain-Derived Neurotrophic Factor Levels—An Ex Vivo Study